• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

What Is and Is Not in Trump's Drug Pricing Plan: An Interview With Dr Michael Chernew

Podcast

American Patients First, President Donald Trump's blueprint to bring down the cost of drug pricing is the result of a campaign promise to drive down out-of-pocket costs for consumers. Those who helped craft the proposal say it represents real reform. However, critics say it goes too easy on the pharmaceutical industry.

American Patients First, President Donald Trump's blueprint to bring down the cost of drug pricing is the result of a campaign promise to drive down out-of-pocket costs for consumers. Those who helped craft the proposal say it represents real reform. However, critics say it goes too easy on the pharmaceutical industry.

Mary Caffrey, the managing editor of The American Journal of Managed Care® (AJMC®)s Evidence-Based series, spoke with Harvard healthcare economist Michael E. Chernew, PhD, who is the co-editor in chief of AJMC®, to discuss elements of the Trump administration proposal to control drug prices. Chernew is also a former vice chair of the Medicare Payment Advisory Commission.

To listen, login to the website.

iTunes: http://apple.co/2eYWTss

TuneIn: http://bit.ly/2gv7iwj

Stitcher: http://bit.ly/2gCqtFg

Listen above or through one of these podcast services:

Read more:

Trump Offers Blueprint to Drive Down Prescription Drug Prices; Targets Rebates, "Middlemen"

Azar Stumps for Plan to Hold Down Prescription Drug Costs

Trump Targets Drug Prices, Right-to-Try in State of the Union

Will Trump Take Steps to Rein in Drug Prices?

Related Videos
Eneline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA
© 2024 MJH Life Sciences
AJMC®
All rights reserved.